about
Exploring the impact of target cell heterogeneity on HIV loads in a within-host model.Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care.Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UKIncarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysisHigh response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programmeEvaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugsEvaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol)Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluationIntegrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community careThe cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UKCost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in EnglandResponse to: Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs
P50
Q51797466-174984AC-0DB1-42E0-9A0B-73E050C4E808Q55187199-8AD2F533-863D-4418-8999-7F90825B3F60Q57700826-60F03B51-45D2-4DFA-9A14-477726BF36D6Q57910003-1E576132-D21C-4B30-A426-4C47B2399FEFQ58598733-5D8D00B0-573B-4607-9EA5-7A60AA0A1AB6Q59351185-19D5B76E-28D2-4BBD-85FE-3D4582CEC2ABQ61912345-079FA6F9-BD2B-44F1-A2B9-8E09A3E54D74Q90261320-CE7FFDA9-D315-43F6-BCBD-D71B3866D141Q90845262-E677285F-7F0A-4DB0-AA0A-6EA115D20008Q91542677-A0C4456A-CC99-467B-AF42-4041E8EC692BQ91542684-212021A6-5D77-4EB5-ACCB-6A4C8DC3293DQ92957761-62C7EFC4-2E68-4F0D-AB61-77B186115394Q96350012-C558FF1D-9AD7-49E6-A5C5-080E114165EB
P50
description
researcher ORCID ID = 0000-0002-0268-988X
@en
wetenschapper
@nl
name
Zoe Ward
@ast
Zoe Ward
@en
Zoe Ward
@es
Zoe Ward
@nl
type
label
Zoe Ward
@ast
Zoe Ward
@en
Zoe Ward
@es
Zoe Ward
@nl
altLabel
Ward Z
@en
prefLabel
Zoe Ward
@ast
Zoe Ward
@en
Zoe Ward
@es
Zoe Ward
@nl
P106
P31
P496
0000-0002-0268-988X